Ironwood Pharmaceuticals (IRWD) Other Accumulated Expenses (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Other Accumulated Expenses data on file, last reported at $6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 20.84% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (down 20.84% YoY), and the FY2025 full-year result was $9.4 million, up 112.92% from the prior year.
• Other Accumulated Expenses retreated to $6.0 million in Q1 2026, from $9.4 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $14.3 million in Q3 2023 to a low of $3.6 million in Q4 2022.
• A 5-year average of $7.1 million and a median of $6.8 million in 2025 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses jumped 257.5% in 2023 and sank 45.45% in 2024, its largest moves.
• Tracing IRWD's Other Accumulated Expenses over 5 years: stood at $3.6 million in 2022, then soared by 72.71% to $6.2 million in 2023, then decreased by 28.71% to $4.4 million in 2024, then surged by 112.92% to $9.4 million in 2025, then tumbled by 36.48% to $6.0 million in 2026.
• Business Quant data shows IRWD's Other Accumulated Expenses at $6.0 million in Q1 2026, $9.4 million in Q4 2025, and $6.8 million in Q3 2025.